CMRX - キメリックス (Chimerix Inc.)

CMRXのニュース

   Chimerix to Present at H.C. Wainwright 23rd Annual Global Investment Conference  2021/09/07 11:00:00 Intrado Digital Media
DURHAM, N.C., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that Mike Sherman, Chief Executive Officer of Chimerix and Mike Andriole, Chief Financial and Business Officer of Chimerix, will participate in a pre-recorded fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference that will be made available on Monday, September 13, 2021 at 7:00 a.m. ET.
   Rhabdoid Tumor Treatment Market SWOT Analysis, Key Indicators, Forecast 2028 : Takeda Pharmaceutical Company Limited, Chimerix, Epizyme, Inc., Vyriad, DNAtrix, Lantern Pharma, Inc., and Pfizer Inc  2021/08/31 09:57:38 OpenPR
Global rhabdoid tumor treatment market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to account to grow at a CAGR of 6.10% in the above mentioned forecast
   Chimerix, Inc. 2021 Q2 - Results - Earnings Call Presentation  2021/08/13 15:18:20 Seeking Alpha
   Chimerix, Inc. (CMRX) CEO Mike Sherman on Q2 2021 Results - Earnings Call Transcript  2021/08/08 08:24:03 Seeking Alpha
   Earnings news: Duke Energy, CommScope, BioCryst, Chimerix | WRAL TechWire  2021/08/05 12:05:49 WRAL TechWire
Duke Energy, CommScope and two biotech firms in the Triangle report their financials as earnings season continues. Here''s the latest: Duke Energy CHARLOTTE -
   Thursday 7/1 Insider Buying Report: CMRX, FOR  2021/07/01 17:50:13 One News Page
As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let''s look at two noteworthy recent insider buys.
   Maxim Group Sticks to Their Buy Rating for Chimerix (CMRX)  2021/06/08 11:15:08 Smarter Analyst
Maxim Group analyst Naureen Quibria reiterated a Buy rating on Chimerix (CMRX) yesterday and set a price target of $20.00. The post Maxim Group Sticks to Their Buy Rating for Chimerix (CMRX) appeared first on Smarter Analyst .
   FDA approves Chimerix''s oral suspension smallpox antiviral, giving treatment option to dysphagic patients  2021/06/08 10:28:15 FiercePharma
FDA approves Chimerix''s oral suspension smallpox antiviral, giving treatment option to dysphagic patients ntaylor Tue, 06/08/2021 - 06:28
   H.C. Wainwright Maintains Their Buy Rating on Chimerix (CMRX)  2021/06/07 10:06:31 Smarter Analyst
H.C. The post H.C. Wainwright Maintains Their Buy Rating on Chimerix (CMRX) appeared first on Smarter Analyst .
   Chimerix (CMRX) Gets a Buy Rating from JonesTrading  2021/06/04 18:45:24 Smarter Analyst
In a report released today, Soumit Roy from JonesTrading reiterated a Buy rating on Chimerix (CMRX), with a price target of $14.00. The post Chimerix (CMRX) Gets a Buy Rating from JonesTrading appeared first on Smarter Analyst .
   Maxim Group Sticks to Their Buy Rating for Chimerix (CMRX)  2021/06/08 11:15:08 Smarter Analyst
Maxim Group analyst Naureen Quibria reiterated a Buy rating on Chimerix (CMRX) yesterday and set a price target of $20.00. The post Maxim Group Sticks to Their Buy Rating for Chimerix (CMRX) appeared first on Smarter Analyst .
   FDA approves Chimerix''s oral suspension smallpox antiviral, giving treatment option to dysphagic patients  2021/06/08 10:28:15 FiercePharma
FDA approves Chimerix''s oral suspension smallpox antiviral, giving treatment option to dysphagic patients ntaylor Tue, 06/08/2021 - 06:28
   H.C. Wainwright Maintains Their Buy Rating on Chimerix (CMRX)  2021/06/07 10:06:31 Smarter Analyst
H.C. The post H.C. Wainwright Maintains Their Buy Rating on Chimerix (CMRX) appeared first on Smarter Analyst .
   Chimerix (CMRX) Gets a Buy Rating from JonesTrading  2021/06/04 18:45:24 Smarter Analyst
In a report released today, Soumit Roy from JonesTrading reiterated a Buy rating on Chimerix (CMRX), with a price target of $14.00. The post Chimerix (CMRX) Gets a Buy Rating from JonesTrading appeared first on Smarter Analyst .
   Chimerix gets FDA approval for TEMBEXA for the treatment of smallpox  2021/06/04 18:18:02 Seeking Alpha

calendar